Last reviewed · How we verify
4D-710
4D-710 is a gene therapy that uses an adeno-associated virus to deliver a functional copy of the CFTR gene to the lungs, correcting the underlying genetic defect in cystic fibrosis.
4D-710 is a gene therapy that uses an adeno-associated virus to deliver a functional copy of the CFTR gene to the lungs, correcting the underlying genetic defect in cystic fibrosis. Used for Cystic fibrosis.
At a glance
| Generic name | 4D-710 |
|---|---|
| Sponsor | 4D Molecular Therapeutics |
| Drug class | Gene therapy |
| Target | CFTR gene |
| Modality | Biologic |
| Therapeutic area | Cystic Fibrosis |
| Phase | Phase 2 |
Mechanism of action
This approach aims to restore normal CFTR protein function, which is essential for the proper functioning of chloride channels in the lungs, thereby improving lung function and reducing the risk of pulmonary exacerbations. By delivering the CFTR gene directly to the lungs, 4D-710 seeks to bypass the need for systemic gene therapy and minimize potential off-target effects.
Approved indications
- Cystic fibrosis
Common side effects
- Pulmonary exacerbations
- Respiratory infections
- Hemoptysis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 4D-710 CI brief — competitive landscape report
- 4D-710 updates RSS · CI watch RSS
- 4D Molecular Therapeutics portfolio CI